A number of labs in the pharma/biotech industry and in academia are now focusing their efforts on new ways to modulate the immune system to target cancer. Advances, both in understanding immune pathways and in developing tools to target and exploit these pathways, have led to remarkable progress in this relatively new field. The Scientist brings together a panel of experts who will delve into the hope and hype in an effort to educate the audience about the new findings in cancer immunotherapy.
Dr. Jedd Wolchok
Chief, Melanoma & Immunotherapeutics Service
Memorial Sloan-Kettering Cancer Center
Dr. Tibor Keler
Senior Vice President and Chief Scientific Officer